PT  - JOURNAL ARTICLE
AU  - Westley C. Evans
AU  - David Gilmore
AU  - Jeffrey English
TI  - The Role of PET and PET/CT in Managing the Care of Lymphoma Patients
AID  - 10.2967/jnmt.110.082982
DP  - 2011 Sep 01
TA  - Journal of Nuclear Medicine Technology
PG  - 190--194
VI  - 39
IP  - 3
4099  - http://tech.snmjournals.org/content/39/3/190.short
4100  - http://tech.snmjournals.org/content/39/3/190.full
SO  - J. Nucl. Med. Technol.2011 Sep 01; 39
AB  - The clinical use of PET and PET/CT aids physicians and patients in developing lymphoma prognoses, specifically for Hodgkin disease and aggressive types of non-Hodgkin lymphoma. PET and PET/CT are used to initially stage lymphoma, restage disease, and check for remission or recurrence of malignant tissue after treatment. PET/CT is more sensitive and specific than CT alone and has better accuracy concerning lymphoma relapse and remission. In conjunction with other tests, such as blood laboratory work and biopsy, PET and PET/CT allow the lymphoma to be staged appropriately and treated correctly. Results from PET and PET/CT contribute to the formation of a specialized treatment plan that leads to the best possible care for each individual patient. PET and PET/CT positively affect the management of patients with lymphoma.